denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Abbvie Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo, Genentech, a member of the Roche Group, Helsinn Healthcare SA and Pfizer Inc
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
AML, Diseases, Lymphoid Malignancies, Myeloid Malignancies
Hematology Disease Topics & Pathways:
AML, Diseases, Lymphoid Malignancies, Myeloid Malignancies
Friday, December 4, 2020: 3:00 PM-6:00 PM
Chair:
Neil Love, MD, Research To Practice
Disclosures:
No relevant conflicts of interest to declare.
Speakers:
Alexander E. Perl, MD, University of Pennsylvania, Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania
,
Daniel A. Pollyea, MD, University of Colorado Denver
,
Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center
,
Andrew H Wei, MBBS, PhD, The Alfred Hospital
and
Mark Levis, MD, PhD, Director, Adult Leukemia Program, Co-Division Director, Hematologic Malignancies, Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine
Disclosures:
Perl: Jazz: Honoraria, Other; Biomed Valley Discoveries: Research Funding; Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company: Consultancy, Honoraria, Other; Bayer HealthCare Pharmaceuticals: Research Funding; New Link Genetics: Honoraria, Other; FUJIFILM Pharmaceuticals USA, Inc: Research Funding; Leukemia & Lymphoma Society, Beat AML: Consultancy; Syndax: Consultancy, Honoraria; Takeda: Honoraria, Other: Travel costs for meeting; AbbVie Inc: Consultancy, Honoraria, Other, Research Funding; Agios: Consultancy, Honoraria, Other; Novartis: Honoraria, Other, Research Funding; Daiichi Sankyo: Consultancy, Honoraria, Other: Writing/editorial support, travel costs for meetings, Research Funding; FORMA Therapeutics: Consultancy, Honoraria, Other; Arog Pharmaceuticals Inc: Other: uncompensated consulting, travel costs for meetings; Actinium Pharmaceuticals Inc: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Other: writing/editorial support, travel costs for meeting presentations related to study, Research Funding. Pollyea: Abbvie: Consultancy, Research Funding; Syros: Consultancy; Syndax: Consultancy; Karyopharm: Consultancy; Novartis: Consultancy; Amgen: Consultancy; Genentech: Consultancy; 47: Consultancy, Research Funding; Janssen: Consultancy; Agios: Consultancy; Glycomimetics: Other; Daiichi Sankyo: Consultancy; Takeda: Consultancy; Pfizer: Consultancy; Celgene/BMS: Consultancy. Stein: Celgene Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Agios Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Consultancy; Syndax: Consultancy, Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bayer: Research Funding; Biotheryx: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; PTC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy; Abbvie: Consultancy; Astellas Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Wei: Janssen: Honoraria; Astra Zeneca: Honoraria, Research Funding; Macrogenics: Honoraria; Roche: Honoraria; Servier: Consultancy, Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Novartis: Honoraria, Research Funding, Speakers Bureau; Abbvie: Honoraria, Research Funding, Speakers Bureau; Pfizer: Honoraria; Walter and Eliza Hall Institute of Medical Research: Patents & Royalties: AW is eligible for royalty payments related to venetoclax; Bristol Myers Squibb: Honoraria, Research Funding, Speakers Bureau. Levis: FujiFilm: Honoraria, Research Funding; Amgen: Honoraria; Menarini: Honoraria; Daiichi-Sankyo: Honoraria; Astellas: Honoraria, Research Funding.
This activity, the third of a 4-part live webinar series, will feature 5 acute myeloid leukemia (AML) investigators serving as faculty. Research To Practice (RTP) president Dr Neil Love will moderate the program. Prior to live webinar, the faculty plus 3 other investigators will complete a survey to ascertain their perspectives on controversial questions and scenarios related to the management of AML. Responses from all 8 investigators will be depicted as Treatment Preference Matrices (TPMs). Additionally, RTP will conduct a Patterns of Care (POC) survey of 75 US general oncologists featuring many of the same questions posed to the experts. Findings from the surveys will serve as the foundation for the FSS virtual program on Dec 4th. The live webcast will be divided into 5 modules, with each featuring 2 segments — (1) discussion of a series of TPMs and (2) corresponding POC survey results and a faculty member-led review of emerging clinical research. Throughout the session, Dr Love will ask participating faculty to discuss the rationale for their TPM responses & shed light on any discrepancies and/or practice gaps. To make the program more interactive, attendees will be able to use RTP’s enhanced webinar interface to pose questions to Dr Neil Love and the faculty as well as to complete a pre-meeting survey, from which the results will be juxtaposed with the TPMs & POC survey results to foster additional debate during the webinar.
For more information, please email us at Meetings@ResearchToPractice.com or call us at 1 (800) 233-6153 (toll free, US only) or +1 (305) 377-2828 (international). To learn more about this webinar series please visit our website: http://www.researchtopractice.com/Meetings/FSS2020.
See more of: Satellite Symposia